Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
| ▸ | MAP1LC3B | Q9GZQ8 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | SLC18A3 | Q16572 | 1/20 | 0.33 |
| ▸ | TRIM24 | O15164 | 1/20 | 0.33 |
| ▸ | TRIM33 | Q9UPN9 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL427801 | 0.97 | ALDH1A1 (0.50) | ALDH1A1MAPTMAPK1MAP1LC3BKMT2A | |
| SCHEMBL7638534 | 0.91 | MAPT (0.44) | ALDH1A1MAPTMAPK1KMT2ATRIM24 | |
| SCHEMBL5471447 | 0.89 | ALDH1A1 (0.42) | ALDH1A1MAPTMAPK1MAP1LC3BKMT2A | |
| SCHEMBL1073890 | 0.88 | ALDH1A1 (0.44) | ALDH1A1MAPTMAPK1KMT2ATRIM24 | |
| SCHEMBL11122429 | 0.88 | ALDH1A1 (0.44) | ALDH1A1MAPTMAPK1KMT2ATRIM24 | |
| SCHEMBL8348766 | 0.88 | ALDH1A1 (0.44) | ALDH1A1MAPTMAPK1KMT2ATRIM24 | |
| SCHEMBL7014418 | 0.88 | ALDH1A1 (0.44) | ALDH1A1MAPTMAPK1KMT2ATRIM24 | |
| SCHEMBL20369294 | 0.87 | ALDH1A1 (0.41) | ALDH1A1MAPTMAP1LC3BKMT2ASLC18A3 | |
| SCHEMBL11824060 | 0.86 | ALDH1A1 (0.44) | ALDH1A1MAPTMAPK1KMT2A | |
| SCHEMBL3295691 | 0.84 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240208914-A1 | AMINOCYCLOBUTANES AS MONOACYLGLYCEROL LIPASE MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2024-06-27 | — | — | US | disclosed |
| CN-115335365-B | Aminocyclobutane as monoacylglycerol lipase modulators | 詹森药业有限公司 | 2024-06-18 | — | — | CN | disclosed |
| US-11919870-B2 | Aminocyclobutanes as monoacylglycerol lipase modulators | JANSSEN PHARMACEUTICA NV (BE) | 2024-03-05 | — | — | US | disclosed |
| US-20230331686-A1 | AMINOCYCLOBUTANES AS MONOACYLGLYCEROL LIPASE MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2023-10-19 | — | — | US | disclosed |
| EP-4126825-A1 | AMINOCYCLOBUTANES AS MONOACYLGLYCEROL LIPASE MODULATORS | Janssen Pharmaceutica NV (BE) | 2023-02-08 | — | — | EP | disclosed |
| US-11512059-B2 | Aminocyclobutanes as monoacylglycerol lipase modulators | JANSSEN PHARMACEUTICA NV (BE) | 2022-11-29 | — | — | US | disclosed |
| CN-115335365-A | Aminocyclobutane as monoacylglycerol lipase modulators | 詹森药业有限公司 | 2022-11-11 | — | — | CN | disclosed |
| US-20210317094-A1 | AMINOCYCLOBUTANES AS MONOACYLGLYCEROL LIPASE MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2021-10-14 | — | — | US | disclosed |
| WO-2021191391-A1 | AMINOCYCLOBUTANES AS MONOACYLGLYCEROL LIPASE MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2021-09-30 | — | — | WO | disclosed |
| EP-2481735-A1 | Substituted heterocyclic derivatives and compositions and their pharmaceutical use as antibacterials | Pfizer Inc. (US) | 2012-08-01 | — | — | EP | disclosed |
| US-20120065188-A1 | SUBSTITUTED HETEROCYCLIC DERIVATIVES AND THEIR PHARMACEUTICAL USE AND COMPOSITIONS | PFIZER INC | 2012-03-15 | — | — | US | disclosed |
| US-20120065188-A1 | SUBSTITUTED HETEROCYCLIC DERIVATIVES AND THEIR PHARMACEUTICAL USE AND COMPOSITIONS | PFIZER INC | 2012-03-15 | — | — | US | disclosed |
| US-20110092480-A1 | Substituted Heterocyclic Derivatives and Their Pharmaceutical Use and Compositions | PFIZER INC. | 2011-04-21 | — | — | US | disclosed |
| US-20110092480-A1 | Substituted Heterocyclic Derivatives and Their Pharmaceutical Use and Compositions | PFIZER INC. | 2011-04-21 | — | — | US | disclosed |
| WO-2008139288-A2 | SUBSTITUTED HETEROCYCLIC DERIVATIVES AND COMPOSITIONS AND THEIR PHARMACEUTICAL USE AS ANTIBACTERIALS | PFIZER INC. (US) | 2008-11-20 | — | — | WO | disclosed |
| US-20080280879-A1 | SUBSTITUTED HETEROCYCLIC DERIVATIVES AND THEIR PHARMACEUTICAL USE AND COMPOSITIONS | PFIZER INC | 2008-11-13 | — | — | US | disclosed |
| US-20080280879-A1 | SUBSTITUTED HETEROCYCLIC DERIVATIVES AND THEIR PHARMACEUTICAL USE AND COMPOSITIONS | PFIZER INC | 2008-11-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11919870-B2 | Aminocyclobutanes as monoacylglycerol lipase modulators | MGLL, DAGLB, FAAH | ALDH1A1 832/4885MAPT 2870/4885MAPK1 3834/4885 |
| US-11512059-B2 | Aminocyclobutanes as monoacylglycerol lipase modulators | MGLL, DAGLB, FAAH | ALDH1A1 832/4885MAPT 2870/4885MAPK1 3834/4885 |
| US-20230331686-A1 | AMINOCYCLOBUTANES AS MONOACYLGLYCEROL LIPASE MODULATORS | MGLL, DAGLB, FAAH | ALDH1A1 832/4885MAPT 2870/4885MAPK1 3834/4885 |
| US-20120065188-A1 | SUBSTITUTED HETEROCYCLIC DERIVATIVES AND THEIR PHARMACEUTICAL USE AND COMPOSITIONS | XDH, CYP2D6, F12 | ALDH1A1 3777/4885MAPT 4323/4885MAPK1 3584/4885 |
| US-20240208914-A1 | AMINOCYCLOBUTANES AS MONOACYLGLYCEROL LIPASE MODULATORS | MGLL, DAGLB, FAAH | ALDH1A1 832/4885MAPT 2870/4885MAPK1 3834/4885 |
| US-20080280879-A1 | SUBSTITUTED HETEROCYCLIC DERIVATIVES AND THEIR PHARMACEUTICAL USE AND COMPOSITIONS | XDH, CYP2D6, F12 | ALDH1A1 3777/4885MAPT 4323/4885MAPK1 3584/4885 |
| US-20110092480-A1 | Substituted Heterocyclic Derivatives and Their Pharmaceutical Use and Compositions | XDH, CYP2D6, F12 | ALDH1A1 3777/4885MAPT 4323/4885MAPK1 3584/4885 |
| US-20210317094-A1 | AMINOCYCLOBUTANES AS MONOACYLGLYCEROL LIPASE MODULATORS | MGLL, DAGLB, FAAH | ALDH1A1 832/4885MAPT 2870/4885MAPK1 3834/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.